Exicure, Inc. (2H0A.F)
| Previous close | 0.4340 |
| Open | 0.4120 |
| Bid | 0.4200 x N/A |
| Ask | 0.4560 x N/A |
| Day's range | 0.4120 - 0.4140 |
| 52-week range | 0.3230 - 1.3000 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 3.661M |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | 0.25 |
| EPS (TTM) | 1.6400 |
| Earnings date | 13 May 2024 - 19 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireExicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
CHICAGO, April 22, 2024--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all pe
Business WireExicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
CHICAGO, February 05, 2024--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.
Simply Wall St.Lacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price Drop
Exicure, Inc. ( NASDAQ:XCUR ) shares have had a horrible month, losing 25% after a relatively good period beforehand...
